810 related articles for article (PubMed ID: 36142538)
1. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.
Liang Z; He Y; Hu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142538
[TBL] [Abstract][Full Text] [Related]
2. Interactions between cardiology and oncology drugs in precision cardio-oncology.
Kamaraju S; Mohan M; Zaharova S; Wallace B; McGraw J; Lokken J; Tierney J; Weil E; Fatunde O; Brown SA
Clin Sci (Lond); 2021 Jun; 135(11):1333-1351. PubMed ID: 34076246
[TBL] [Abstract][Full Text] [Related]
3. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention.
Perry TR; Roberts ML; Sunkara B; Maddula R; McLeish T; Gomez J; Lucas J; Rayan D; Patel S; Liang M; Bosnjak ZJ; Brown SA
Curr Oncol Rep; 2021 May; 23(7):77. PubMed ID: 33937943
[TBL] [Abstract][Full Text] [Related]
4. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
5. Optimizing cardio-oncology programs for cancer patients.
Francis SA; Asnani A; Neilan T; Scherrer-Crosbie M
Future Oncol; 2015; 11(14):2011-5. PubMed ID: 26198828
[No Abstract] [Full Text] [Related]
6. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
Jovenaux L; Cautela J; Resseguier N; Pibarot M; Taouqi M; Orabona M; Pinto J; Peyrol M; Barraud J; Laine M; Bonello L; Paganelli F; Barlesi F; Thuny F
Int J Cardiol; 2017 Aug; 241():387-392. PubMed ID: 28365180
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
8. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
9. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Andres MS; Pan J; Lyon AR
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839
[TBL] [Abstract][Full Text] [Related]
10. European Society of Cardiology Core Curriculum for cardio-oncology.
López-Fernández T; Farmakis D; Ameri P; Asteggiano R; de Azambuja E; Aznar M; Barac A; Bayes-Genis A; Bax JJ; Bergler-Klein J; Boriani G; Celutkiene J; Coats A; Cohen-Solal A; Córdoba R; Cosyns B; Filippatos G; Fox K; Gulati G; Inciardi RM; Lee G; Mamas MA; Novo G; Plummer C; Psyrri A; Rakisheva A; Suter T; Tini G; Tocchetti CG; Toutouzas K; Wilhelm M; Metra M; Lyon AR; Rosano GMC
Eur J Heart Fail; 2024 Apr; 26(4):754-771. PubMed ID: 38059343
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.
Tilemann LM; Heckmann MB; Katus HA; Lehmann LH; Müller OJ
Clin Res Cardiol; 2018 Apr; 107(4):271-280. PubMed ID: 29453595
[TBL] [Abstract][Full Text] [Related]
12. [The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].
Romann SW; Frey N; Lehmann L
Dtsch Med Wochenschr; 2024 Jun; 149(12):719-723. PubMed ID: 38781996
[TBL] [Abstract][Full Text] [Related]
13. The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology.
Fatunde OA; Brown SA
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963461
[TBL] [Abstract][Full Text] [Related]
14. Rationale and proposal for cardio-oncology services in Italy.
Galderisi M; Santoro C; Bossone E; Mancusi C
J Cardiovasc Med (Hagerstown); 2022 Apr; 23(4):207-215. PubMed ID: 32858628
[TBL] [Abstract][Full Text] [Related]
15. Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.
Biasillo G; Cipolla CM; Cardinale D
Curr Oncol Rep; 2017 Aug; 19(8):55. PubMed ID: 28707189
[TBL] [Abstract][Full Text] [Related]
16. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
17. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
[TBL] [Abstract][Full Text] [Related]
18. Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope.
Mittal R; Krishnan M P S; Saxena R; Sampath A; Goyal B
Cancer Treat Res Commun; 2023; 36():100750. PubMed ID: 37531735
[TBL] [Abstract][Full Text] [Related]
19. Cardio-oncology: the new frontier of clinical and preventive cardiology.
Paris S; Tarantini L; Navazio A; Faggiano P
Monaldi Arch Chest Dis; 2020 Jun; 90(2):. PubMed ID: 32571000
[TBL] [Abstract][Full Text] [Related]
20. Understanding Myocardial Metabolism in the Context of Cardio-Oncology.
Liu J; Chen ZZ; Patel J; Asnani A
Heart Fail Clin; 2022 Jul; 18(3):415-424. PubMed ID: 35718416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
